

CITATION REPORT

List of articles citing

A comparison of the aldosterone-blocking agents eplerenone and spironolactone

DOI: 10.1002/clc.20324
Clinical Cardiology, 2008, 31, 153-8.

Source: <https://exaly.com/paper-pdf/43579577/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
171	Safety and Efficacy of Eplerenone in the Management of Essential Hypertension. 2009 , 1, CMT.S2211		
170	Increased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to monotherapies--the effect on podocytes. 2009 , 24, 3640-51		19
169	A comparison of the aldosterone-blocking agents eplerenone and spironolactone. <i>Clinical Cardiology</i> , 2009 , 32, 230	3.3	3
168	Current world literature. 2009 , 16, 260-77		
167	Aortic cell apoptosis in rat primary aldosteronism model. 2010 , 30, 385-90		4
166	Aldosterone inhibition and cardiovascular protection: more important than it once appeared. 2010 , 24, 345-50		26
165	The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. 2010 , 157, 282-7		46
164	Aldosterone receptor blockade inhibits degenerative processes in the early stage of calcific aortic stenosis. 2010 , 642, 107-12		12
163	The mineralocorticoid receptor as a novel player in skin biology: beyond the renal horizon?. 2010 , 19, 100-7		35
162	Aldosterone receptor inhibition alters the viscoelastic biomechanical behavior of the aortic wall. 2010 , 235, 311-6		4
161	Principales componentes del sistema renina-angiotensina-aldosterona: historia, modulaci3n farmacol3gica e impacto cl3nico. 2010 , 21, 516-529		1
160	Aldosterone receptor antagonists: effective but often forgotten. 2010 , 121, 934-9		65
159	Sensitivity of NOS-dependent vascular relaxation pathway to mineralocorticoid receptor blockade in caveolin-1-deficient mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010 , 298, H1776-88	5.2	34
158	Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. 2010 , 24, 387-94		24
157	Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations. 2010 , 5, 1330-9		42
156	Management of chronic cardiorenal syndrome. 2010 , 165, 129-139		6
155	Thirst and hydration: physiology and consequences of dysfunction. 2010 , 100, 15-21		130

154	Novel therapeutic targets for hypertension. <i>Nature Reviews Cardiology</i> , 2010 , 7, 431-41	14.8	89
153	The RAAS in the pathogenesis and treatment of diabetic nephropathy. 2010 , 6, 319-30		198
152	Which antihypertensive drugs are the most nephroprotective and why?. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 2651-63	4	15
151	Danshen extract 15,16-dihydrotanshinone I functions as a potential modulator against metabolic syndrome through multi-target pathways. 2010 , 120, 155-63		31
150	Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy. 2010 , 50, 439-65		240
149	Effect of eplerenone versus spironolactone on cortisol and hemoglobin A _{1c} levels in patients with chronic heart failure. 2010 , 160, 915-21		87
148	The importance of renin-angiotensin blockade in patients with cardio-renal disease. 2010 , 36 Suppl 1, 97-105		2
147	Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice. 2010 , 40, 540-9		15
146	ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference. 2010 , 25, 2077-89		24
145	Análisis coste-efectividad de eplerenona en pacientes con insuficiencia cardiaca post-infarto agudo de miocardio. 2011 , 8, 39-50		
144	The month after a novel tale on eplerenone, but with a different ending. 2011 , 58, 1967-9		
143	Emerging drugs which target the renin-angiotensin-aldosterone system. 2011 , 16, 619-30		23
142	Drug Discovery and Evaluation: Methods in Clinical Pharmacology. 2011 , 489-521		
141	Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure. 2011 , 7, 353-63		31
140	Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. 2011 , 6, e26904		35
139	A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. 2011 , 29, 980-90		151
138	Safety aspects of aldosterone-blocking drugs. 2011 , 13, B40-B42		
137	Physiology of aldosterone and pharmacology of aldosterone blockers. 2011 , 13, B27-B30		8

136	SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na ⁺ excretion activity. 2011 , 115, 346-53		32
135	Effects of aldosterone and related steroids on LPS-induced increased expression of inducible NOS in rat aortic smooth muscle cells. 2011 , 164, 2003-14		4
134	Drug therapy for resistant hypertension: simplifying the approach. 2011 , 13, 120-30		29
133	Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 8616-31	8.3	74
132	Angiotensin inhibition and longevity: a question of hydration. 2011 , 461, 317-24		13
131	Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. <i>European Heart Journal</i> , 2011 , 32, 2626-33	9.5	32
130	Macrophage activation is responsible for loss of anticontractile function in inflamed perivascular fat. 2011 , 31, 908-13		87
129	Central interactions of aldosterone and angiotensin II in aldosterone- and angiotensin II-induced hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011 , 300, H555-64	5.2	82
128	Antiapolipoprotein A-1 IgG chronotropic effects require nongenomic action of aldosterone on L-type calcium channels. 2012 , 153, 1269-78		16
127	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. <i>European Heart Journal</i> , 2012 , 33, 2782-95	9.5	121
126	Hypertension in the elderly. 2012 , 4, 135-47		112
125	Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial. 2012 , 5, 586-93		14
124	Antioxidants in kidney diseases: the impact of bardoxolone methyl. 2012 , 2012, 321714		37
123	SM-368229, a novel promising mineralocorticoid receptor antagonist, shows antihypertensive efficacy with minimal effect on serum potassium level in rats. 2012 , 59, 458-64		26
122	Eplerenone improved hypokalemia in a patient with Gitelman's syndrome. 2012 , 51, 83-6		18
121	Spironolactone, but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome. 2012 , 74, 1015-22		15
120	Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. 2012 , 18, 265-81		42
119	Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure. 2012 , 32, 827-37		8

118	Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial. 2012 , 12, 19	23
117	Effect of eplerenone, a selective aldosterone blocker, on the development of diabetic nephropathy in type 2 diabetic rats. 2012 , 36, 128-35	11
116	Mineralocorticoid receptors mediate cardiac remodelling in morphine-dependent rats. 2012 , 111, 75-80	9
115	Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms. 2013 , 73, 1451-62	10
114	Design, synthesis, and structure-activity relationships of dihydrofuran-2-one and dihydropyrrol-2-one derivatives as novel benzoxazin-3-one-based mineralocorticoid receptor antagonists. 2013 , 21, 5983-94	26
113	Mineralocorticoid receptor antagonists: their use and differentiation in Japan. 2013 , 36, 185-90	13
112	Effectiveness and safety of spironolactone for systolic heart failure. 2013 , 112, 1427-32	13
111	Spironolactone in mild chronic heart failure: insights from a propensity-matched analysis of the MUSIC study cohort. 2013 , 168, 4525-7	3
110	Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism. 2013 , 33, 265-76	15
109	Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease. 2013 , 6, 1527-1531	10
108	Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXR α activation. 2013 , 210, 2675-92	41
107	Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. 2014 , 2014, 406960	282
106	Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. <i>European Journal of Heart Failure</i> , 2014 , 16, 143-50	12,3 19
105	The velocity of home blood pressure reduction in response to low-dose eplerenone combined with other antihypertensive drugs determined by exponential decay function analysis. 2014 , 36, 83-91	2
104	Comparison of agents that affect aldosterone action. 2014 , 34, 285-306	23
103	Efficacy of mineralocorticoid receptor antagonism in the acute myocardial infarction phase: eplerenone versus spironolactone. 2015 , 2, 150-158	15
102	Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. 2015 , 46, 439-44	39
101	Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case. 2015 , 9, 235-8	7

100	A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE. 2015 , 11, 177-181		
99	Diuretic Therapy in Heart Failure - Current Approaches. 2015 , 10, 42-47		31
98	Emerging cardiovascular indications of mineralocorticoid receptor antagonists. 2015 , 26, 201-11		23
97	Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods. 2015 , 29, 1109-22		6
96	Personalizing the diuretic treatment of hypertension: the need for more clinical and research attention. 2015 , 17, 542		2
95	Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism. 2015 , 3, 993-1003		20
94	Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone. 2015 , 200, 3-7		11
93	Effect of Selective Mineralocorticoid Receptor Blockade on Flow-Mediated Dilation and Insulin Resistance in Older Adults with Metabolic Syndrome. 2015 , 13, 356-61		8
92	Relationship Between Aldosterone and Parathyroid Hormone, and the Effect of Angiotensin and Aldosterone Inhibition on Bone Health. 2015 , 13, 194-205		4
91	Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure?. 2015 , 20, 283-90		10
90	Outpatient management of chronic heart failure. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 17-41	4	2
89	Estimation of the Mechanism of Adrenal Action of Endocrine-Disrupting Compounds Using a Computational Model of Adrenal Steroidogenesis in NCI-H295R Cells. 2016 , 2016, 4041827		6
88	Spironolactone provides protection from renal fibrosis by inhibiting the endothelial-mesenchymal transition in isoprenaline-induced heart failure in rats. 2016 , 10, 1581-8		8
87	Foundations of Pharmacotherapy for Heart Failure With Reduced Ejection Fraction: Evidence Meets Practice, Part II. 2016 , 31, 545-554		4
86	CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY. <i>Retina</i> , 2016 , 36, 611-8	3.6	58
85	Eplerenone in patients with chronic recurring central serous chorioretinopathy. 2016 , 26, 479-84		21
84	Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: A Comparative Analysis. 2016 , 56, 17-22		29
83	Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1435-48	4	21

82	The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure. 2016 , 15, 659-65		8
81	Pulsatile Cortisol Feedback on ACTH Secretion Is Mediated by the Glucocorticoid Receptor and Modulated by Gender. 2016 , 101, 4094-4102		18
80	Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Clinical Cardiology</i> , 2016 , 39, 285-90	3.3	7
79	Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials. 2016 , 10, 671-82		13
78	Eplerenone use in primary aldosteronism during pregnancy. 2016 , 4, 81-2		14
77	Safety and cardiovascular effects of mineralocorticoid receptor antagonists for patients receiving hemodialysis: a systematic review and meta-analysis. 2016 , 38, 589-99		6
76	Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis. 2016 , 18, 672-8		27
75	Optimizing Cardiovascular Care With Mineralocorticoid Receptor Antagonists. 2017 , 13, 156-161		
74	Eplerenone for hypertension. 2017 , 2, CD008996		16
73	Steroidal Mineralocorticoid Receptor Antagonists: Synthesis and Biology. 2017 , 2, 175-189		2
72	Genomic and rapid effects of aldosterone: what we know and do not know thus far. 2017 , 22, 65-89		32
71	Evaluation and Management of Erectile Dysfunction in the Hypertensive Patient. <i>Current Cardiology Reports</i> , 2017 , 19, 89	4.2	15
70	Impact of Adrenal Steroids on Regulation of Adipose Tissue. <i>Comprehensive Physiology</i> , 2017 , 7, 1425-1447		22
69	Mineralocorticoid receptor antagonists attenuate exaggerated exercise pressor reflex responses in hypertensive rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017 , 313, H788-H794	5.2	6
68	Comparison of two mineralocorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. <i>International Ophthalmology</i> , 2017 , 37, 1115-1125	2.2	32
67	Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017 , 3, 48-57	6.4	48
66	Derangements in adrenergic-adipokine signalling establish a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018 , 20, 873-878	12.3	25
65	Drug therapies in chronic heart failure: a focus on reduced ejection fraction. <i>Clinical Medicine</i> , 2018 , 18, 138-145	1.9	7

64	A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR). <i>Retina</i> , 2018 , 38, 962-969	3.6	50
63	Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. <i>British Journal of Ophthalmology</i> , 2018 , 102, 1060-1065	5.5	22
62	Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study. <i>Clinical Research in Cardiology</i> , 2018 , 107, 49-59	6.1	14
61	Mineralocorticoid receptor antagonism protects the aorta from vascular smooth muscle cell proliferation and collagen deposition in a rat model of adrenal aldosterone-producing adenoma. <i>Journal of Physiology and Biochemistry</i> , 2018 , 74, 17-24	5	16
60	The mineralocorticoid receptor antagonist spironolactone reduces alcohol self-administration in female and male rats. <i>Pharmacology Biochemistry and Behavior</i> , 2018 , 175, 10-18	3.9	9
59	Ventricular-Assist Devices and Kidney Disease. 2018 ,		
58	The Effects of Eplerenone on the Circadian Blood Pressure Pattern and Left Ventricular Hypertrophy in Patients with Obstructive Sleep Apnea and Resistant Hypertension-A Randomized, Controlled Trial. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	10
57	Mineralocorticoid Receptor Antagonists Stimulate Human Hair Growth ex vivo. <i>Skin Pharmacology and Physiology</i> , 2019 , 32, 344-348	3	1
56	Spironolactone inhibits endothelial-mesenchymal transition via the adenosine A2A receptor to reduce cardiorenal fibrosis in rats. <i>Life Sciences</i> , 2019 , 224, 177-186	6.8	7
55	Effects of combined glucocorticoid/mineralocorticoid receptor modulation (CORT118335) on energy balance, adiposity, and lipid metabolism in male rats. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019 , 317, E337-E349	6	4
54	Medical Therapy for Heart Failure Caused by Ischemic Heart Disease. <i>Circulation Research</i> , 2019 , 124, 1520-1535	15.7	59
53	Mineralocorticoid receptor function and cognition in health and disease. <i>Psychoneuroendocrinology</i> , 2019 , 105, 25-35	5	18
52	Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 1385-1406	8.3	10
51	Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response. <i>Oncogene</i> , 2019 , 38, 3103-3118	9.2	14
50	Separate and interacting effects of the endogenous circadian system and behaviors on plasma aldosterone in humans. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2019 , 316, R157-R164	3.2	13
49	Synthesis and Biological Activity of a Bis-steroid-Methanocyclobutanaphthalene- dione Derivative against Ischemia/Reperfusion Injury via Calcium Channel Activation. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2020 , 19, 393-412	2	0
48	Mineralocorticoid receptor antagonists lead to increased adenosine bioavailability and modulate contractile cardiac parameters. <i>Heart and Vessels</i> , 2020 , 35, 719-730	2.1	1
47	Central Serous Chorioretinopathy: Multimodal Imaging and Management Options. <i>Case Reports in Ophthalmological Medicine</i> , 2020 , 2020, 8890404	0.7	2

46	Oral Eplerenone Versus Observation in the Management of Acute Central Serous Chorioretinopathy: A Prospective, Randomized Comparative Study. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	1
45	Comparison between Spironolactone and Eplerenone on LV Systolic Function in Patients with Chronic Heart Failure. <i>University Heart Journal</i> , 2020 , 16, 65-70	0	
44	Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. <i>Nature Reviews Cardiology</i> , 2020 , 17, 641-655	14.8	41
43	Aldosterone-induced hypertension is sex-dependent, mediated by T cells and sensitive to GPER activation. <i>Cardiovascular Research</i> , 2021 , 117, 960-970	9.9	3
42	Pharmacotherapeutic principles of fluid management in heart failure. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 595-610	4	0
41	Inhibitors of Nucleotide Excision Repair Decrease UVB-Induced Mutagenesis-An In Vitro Study. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	0
40	A Review of the Pharmacological Activities and Recent Synthetic Advances of β Butyrolactones. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	8
39	High-dose spironolactone lacks effectiveness in treatment of fibromyalgia (RCT). <i>European Journal of Pain</i> , 2021 , 25, 1739-1750	3.7	0
38	Metabolite Profiling of Malaysian Reveals Eplerenone as Novel Antibacterial Compound for Drug Repurposing Against MDR Bacteria. <i>Frontiers in Microbiology</i> , 2021 , 12, 653562	5.7	1
37	The Effects of Spironolactone and Eplerenone on Left Ventricular Function Using Echocardiography in Symptomatic Patients With New-Onset Systolic Heart Failure: A Comparative Randomised Controlled Trial. <i>Heart Lung and Circulation</i> , 2021 , 30, 1292-1301	1.8	0
36	Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. <i>Diabetes/Metabolism Research and Reviews</i> , 2021 , e3494	7.5	6
35	Hypertension Drug Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1177, 149-268	3.6	3
34	The Impact Exerted on Clinical Outcomes of Patients With Chronic Heart Failure by Aldosterone Receptor Antagonists: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine Research</i> , 2017 , 9, 130-142	2.9	3
33	Efficacy of Drug Eplerenone in the Management of Chronic Central Serous Chorioretinopathy. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2019 , 6, 3280-3284	0	1
32	Differential efficacy profile of aldosterone receptor antagonists, depending on the type of chronic heart failure, whether with reduced or preserved left ventricular ejection fraction-results of a meta-analysis of randomized controlled trials. <i>Cardiovascular Diagnosis and Therapy</i> , 2017 , 7, 272-287	2.6	3
31	Adverse Effects of Mineralocorticoid Receptor Antagonist Administration. <i>Current Pharmaceutical Design</i> , 2018 , 24, 5537-5541	3.3	5
30	Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions. <i>Cardiology Journal</i> , 2016 , 23, 591-598	1.4	8
29	Water, electrolytes and acidBase balance. 2009 , 649-680		1

28	Aldosterone blockade. 2011 , 253-257		
27	Pharmacologic Treatment of Childhood Hypertension. 2013 , 539-555		1
26	[Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015]. <i>Terapevticheskii Arkhiv</i> , 2015 , 87, 77-83	0.9	
25	Ascites and Its Complications. 2087-2106		
24	Diuretics in Heart Failure. 2018 , 53-70		
23	Mineralocorticoid Receptor Antagonist Eplerenone in Cardiovascular Disease. <i>Cardiologia Croatica</i> , 2019 , 14, 263-269	0	
22	Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 1-17	5.9	3
21	Real world comparison of spironolactone and eplerenone in patients with heart failure.. <i>European Journal of Internal Medicine</i> , 2022 ,	3.9	0
20	Advances in the Treatment Strategies in Hypertension: Present and Future.. <i>Journal of Cardiovascular Development and Disease</i> , 2022 , 9,	4.2	0
19	Coronavirus Disease 2019 and Hypertension: How Anti-Hypertensive Drugs Affect COVID-19 Medications and Vice Versa.. <i>Current Drug Safety</i> , 2022 ,	1.4	
18	Diuretics in Treatment of Heart Failure. 2022 , 2, 86-93		
17	Primary aldosteronism in pregnancy.. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022 , 1	10.5	1
16	Genetic Profiling of Glucocorticoid (NR3C1) and Mineralocorticoid (NR3C2) Receptor Polymorphisms before Starting Therapy with Androgen Receptor Inhibitors: A Study of a Patient Who Developed Toxic Myocarditis after Enzalutamide Treatment. <i>Biomedicines</i> , 2022 , 10, 1271	4.8	
15	Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist. <i>Journal of Medicinal Chemistry</i> ,	8.3	0
14	Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. <i>European Heart Journal</i> ,	9.5	0
13	Unilateral recurrent central serous chorioretinopathy (CSCR) following COVID-19 vaccination- A multimodal imaging study. <i>American Journal of Ophthalmology Case Reports</i> , 2022 , 27, 101644	1.3	0
12	Diuretics in Cirrhotic Patients with Ascites. 2022 , 167-178		0
11	Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure. 2022 , 23, 11336		1

- 10 Finerenone: A New Era for Mineralocorticoid Receptor Antagonism and Cardiorenal Protection. **2022**, 47, 101386
- 9 Synthesis of β -Butyrolactone Derivatives from Dihydrotagetone and Evaluation of Their Antidiabetic Activity. **2022**, 7,
- 8 The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management.
- 7 Impact of the Renin-Angiotensin System on the Pathogeny and Pharmacotherapeutics of Neurodegenerative Diseases. **2022**, 12, 1429
- 6 Mineralocorticoid Receptor Pathway Is a Key Mediator of Carfilzomib-induced Nephrotoxicity: Preventive Role of Eplerenone. **2022**, 6, e791
- 5 Repurposable Drugs That Interact with Steroid Responsive Gene Targets for Inner Ear Disease. **2022**, 12, 1641
- 4 Continuous Eplerenone treatment in chronic central serous chorioretinopathy: long-term results from a pilot study.
- 3 Asymmetric Synthesis of β -Spiro- β -Lactones and β -Substituted β -Lactones via Chiral Bifunctional Sulfide-Catalyzed Bromolactonizations.
- 2 Aktuelle **Bersicht** zur androgenetischen Alopecie bei Kindern und Jugendlichen. **2023**, 21, 19-26
- 1 Pediatric androgenetic alopecia: an updated review. **2023**, 21, 19-25